Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 14/20 | 0.74 |
| ▸ | PDGFRA | P16234 | 11/20 | 0.74 |
| ▸ | BCR | P11274 | 8/20 | 0.74 |
| ▸ | PDGFRB | P09619 | 6/20 | 0.74 |
| ▸ | PRKCA | P17252 | 2/20 | 0.74 |
| ▸ | EGFR | P00533 | 2/20 | 0.73 |
| ▸ | BRAF | P15056 | 1/20 | 0.72 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.72 |
| ▸ | KIT | P10721 | 5/20 | 0.69 |
| ▸ | KDR | P35968 | 2/20 | 0.69 |
| ▸ | JAK3 | P52333 | 1/20 | 0.65 |
| ▸ | BTK | Q06187 | 1/20 | 0.65 |
| ▸ | ITK | Q08881 | 1/20 | 0.65 |
| ▸ | LYN | P07948 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1408878 | 0.90 | ABL1 (0.72) | ABL1PDGFRABCRPDGFRBPRKCA | |
| SCHEMBL27841120 | 0.88 | ABL1 (0.79) | ABL1PDGFRABCRPDGFRBPRKCA | |
| SCHEMBL1449867 | 0.87 | ABL1 (0.71) | ABL1PDGFRABCRPDGFRBPRKCA | |
| SCHEMBL1448495 | 0.87 | ABL1 (0.70) | ABL1PDGFRABCRPDGFRBPRKCA | |
| SCHEMBL3219529 | 0.87 | ABL1 (0.77) | ABL1PDGFRABCRPDGFRBPRKCA | |
| SCHEMBL5185763 | 0.86 | ABL1 (0.83) | ABL1PDGFRABCRPDGFRBPRKCA | |
| SCHEMBL13492488 | 0.86 | ABL1 (0.76) | ABL1PDGFRABCRPDGFRBPRKCA | |
| SCHEMBL29441265 | 0.85 | ABL1 (0.77) | ABL1PDGFRABCRPDGFRBPRKCA | |
| SCHEMBL868006 | 0.85 | ABL1 (0.77) | ABL1PDGFRABCRPDGFRBPRKCA | |
| SCHEMBL9666 | 0.85 | PDGFRA (1.00) | ABL1PDGFRABCRPDGFRBPRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101068805-B | Novel phenylaminopyrimidine derivatives as inhibitors of BCR-ABL kinase | NATCO PHARMA LTD | 2013-04-03 | — | — | CN | claimed |
| EP-1786799-B1 | NOVEL PHENYLAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF BCR-ABL KINASE | NATCO PHARMA LTD (IN) | 2012-07-04 | — | — | EP | claimed |
| US-7910598-B2 | Condensing (3-trifluoromethylsulfonyl) benzoyl chloride and 4-methyl-2-nitro-aniline; reducing nitro group with stannous chloride; condensing amino group with cyanamide; cyclocondensing guanidine group with 3-dimethylamino-1-pyridin-3-yl-propenone; antiproliferative agents | NATCO PHARMA LIMITED (IN) | 2011-03-22 | — | — | US | claimed |
| EP-1786799-A1 | NOVEL PHENYLAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF BCR-ABL KINASE | Natco Pharma Limited (IN) | 2007-05-23 | — | — | EP | claimed |
| WO-2006027795-A1 | NOVEL PHENYLAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF BCR-ABL KINASE | NATCO PHARMA LIMITED (IN) | 2006-03-16 | — | — | WO | claimed |
| US-9895367-B2 | Formulation comprising phenylaminopyrimidine derivative as active agent | NATCO PHARMA LIMITED (IN) | 2018-02-20 | — | — | US | disclosed |
| EP-2295424-B1 | Processes for the preparation of novel phenylaminopyrimidine derivatives as inhibitors of BCR-ABL kinase | NATCO PHARMA LTD (IN) | 2015-10-14 | — | — | EP | disclosed |
| EP-2683381-B1 | FORMULATION COMPRISING PHENYLAMINOPYRIMIDINE DERIVATIVE AS ACTIVE AGENT | NATCO PHARMA LTD (IN) | 2015-09-16 | — | — | EP | disclosed |
| EP-2683381-A1 | FORMULATION COMPRISING PHENYLAMINOPYRIMIDINE DERIVATIVE AS ACTIVE AGENT | Natco Pharma Limited (IN) | 2014-01-15 | — | — | EP | disclosed |
| US-20130338180-A1 | FORMULATION COMPRISING PHENYLAMINOPYRIMIDINE DERIVATIVE AS ACTIVE AGENT | NATCO PHARMA LIMITED (IN) | 2013-12-19 | — | — | US | disclosed |
| WO-2012120328-A1 | FORMULATION COMPRISING PHENYLAMINOPYRIMIDINE DERIVATIVE AS ACTIVE AGENT | NATCO PHARMA LIMITED (IN) | 2012-09-13 | — | — | WO | disclosed |
| EP-1786799-B1 | NOVEL PHENYLAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF BCR-ABL KINASE | NATCO PHARMA LTD (IN) | 2012-07-04 | — | — | EP | disclosed |
| US-8183253-B2 | Condensing (3-trifluoromethylsulfonyl) benzoyl chloride and 4-methyl-2-nitro-aniline; reducing nitro group with stannous chloride; condensing amino group with cyanamide; cyclocondensing guanidine group with 3-dimethylamino-1-pyridin-3-yl-propenone; antiproliferative agents; chronic myeloid leukemia | NATCO PHARMA LIMITED (IN) | 2012-05-22 | — | — | US | disclosed |
| US-7910598-B2 | Condensing (3-trifluoromethylsulfonyl) benzoyl chloride and 4-methyl-2-nitro-aniline; reducing nitro group with stannous chloride; condensing amino group with cyanamide; cyclocondensing guanidine group with 3-dimethylamino-1-pyridin-3-yl-propenone; antiproliferative agents | NATCO PHARMA LIMITED (IN) | 2011-03-22 | — | — | US | disclosed |
| EP-2295424-A1 | Processes for the preparation of novel phenylaminopyrimidine derivatives as inhibitors of BCR-ABL kinase | Natco Pharma Limited (IN) | 2011-03-16 | — | — | EP | disclosed |
| US-20080306100-A1 | PHENYLAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF BCR-ABL KINASE | NATCO PHARMA LIMITED (IN) | 2008-12-11 | — | — | US | disclosed |
| US-20070232633-A1 | Novel phenylaminopyrimidine derivatives as inhibitors of BCR-ABL kinase | NATCO PHARMA LIMITED (IN) | 2007-10-04 | — | — | US | disclosed |
| EP-1786799-A1 | NOVEL PHENYLAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF BCR-ABL KINASE | Natco Pharma Limited (IN) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006027795-A1 | NOVEL PHENYLAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF BCR-ABL KINASE | NATCO PHARMA LIMITED (IN) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130338180-A1 | FORMULATION COMPRISING PHENYLAMINOPYRIMIDINE DERIVATIVE AS ACTIVE AGENT | RET, ABL1, ERBB2 | ABL1 2/4885PDGFRA 84/4885BCR 6/4885 |
| US-20070232633-A1 | Novel phenylaminopyrimidine derivatives as inhibitors of BCR-ABL kinase | ABL1, ABL2, BCR | ABL1 1/4885PDGFRA 9/4885BCR 3/4885 |
| US-20080306100-A1 | PHENYLAMINOPYRIMIDINE DERIVATIVES AS INHIBITORS OF BCR-ABL KINASE | ABL1, ABL2, BCR | ABL1 1/4885PDGFRA 113/4885BCR 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.